Oramed spins off oral insulin into OraTech JV with HTIT; $75M total investment, Nasdaq IPO planned

ORAMED PHARMACEUTICALS INC.

HTIT to invest $60M, Oramed $15M into OraTech; Oramed shareholders to receive direct stake in new Nasdaq-listed company.
OraTech to launch Phase 3 trial of oral insulin (ORMD-0801) in US this quarter with revised protocol.
HTIT provides supply agreement for oral insulin capsules; OraTech gets global marketing rights to Oramed's POD technology.
OraTech also receives license for oral semaglutide (HT01B) from HTIT for markets outside greater China.
Initial closing deadline extended to April 30, 2025; second closing by May 31, 2025 if Nasdaq listing delayed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.